Ayman B Ibrahim
Overview
Explore the profile of Ayman B Ibrahim including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
9
Citations
140
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Yardley D, Reeves J, Dees E, Osborne C, Paul D, Ademuyiwa F, et al.
Clin Breast Cancer
. 2016 Aug;
16(6):471-479.e1.
PMID: 27569274
Background: Use of antiangiogenic agents in treatment of metastatic breast cancer (MBC) remains controversial. We evaluated the efficacy and safety of ramucirumab and eribulin versus eribulin alone as third- to...
2.
Saab S, Ibrahim A, Surti B, Durazo F, Han S, Yersiz H, et al.
Liver Int
. 2008 Jul;
28(8):1087-94.
PMID: 18662279
Objective: With an increasing number of liver transplant recipients living, understanding quality-of-life issues is essential. Our goal is to identify pretransplant variables associated with post-transplant quality of life in liver...
3.
Saab S, Wiese C, Ibrahim A, Peralta L, Durazo F, Han S, et al.
Liver Transpl
. 2007 Sep;
13(9):1330-8.
PMID: 17763388
The purposes of liver transplantation (LT) include the extension of survival, improvement in quality of life, and the return of the recipient as a contributing member of society. Employment is...
4.
Saab S, Oh M, Ibrahim A, Durazo F, Han S, Yersiz H, et al.
Liver Transpl
. 2007 Jun;
13(7):1032-8.
PMID: 17600345
Adherence to antiviral therapy is essential to achieve sustained virological responses in patients treated for hepatitis C. An important limitation to use of appropriate doses of ribavirin is development of...
5.
Saab S, Landaverde C, Ibrahim A, Durazo F, Han S, Yersiz H, et al.
Exp Clin Transplant
. 2006 Jul;
4(1):395-9.
PMID: 16827633
Background: The Model for End-Stage Liver Disease (MELD) score is a measure of chronic liver disease severity. Patients awaiting transplantation are assessed using this score. However, it has recently been...
6.
Saab S, Ibrahim A, Shpaner A, Younossi Z, Lee C, Durazo F, et al.
Liver Transpl
. 2005 Jan;
11(2):218-23.
PMID: 15666392
Previous studies have demonstrated an association between Child Turcotte-Pugh (CTP) class and impaired quality of life. However, the relationship between the model for end-stage liver disease (MELD) score and quality...
7.
Saab S, Ghobrial R, Ibrahim A, Kunder G, Durazo F, Han S, et al.
Am J Transplant
. 2003 Aug;
3(9):1167-72.
PMID: 12919097
Hepatitis C (HCV)-positive liver grafts have been increasingly used in patients with decompensated liver disease from HCV because of critical shortage of available organs. Fifty-nine recipients of HCV-positive grafts were...
8.
Saab S, Wang V, Ibrahim A, Durazo F, Han S, Farmer D, et al.
Liver Transpl
. 2003 May;
9(5):473-6.
PMID: 12740789
The Model for End-Stage Liver Disease (MELD) is an important predictor in patients awaiting orthotopic liver transplantation (OLT). However, the model's association with posttransplant patient survival is unclear. We studied...
9.
Saab S, Hu R, Ibrahim A, Goldstein L, Kunder G, Durazo F, et al.
Am J Transplant
. 2003 Mar;
3(3):328-33.
PMID: 12614290
Hepatitis C virus (HCV) recurrence is a serious problem after orthotopic liver transplantation (OLT). The role of ribavirin as a single agent to treat recurrent HCV is controversial. Our aim...